{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:01:03Z","timestamp":1791687663581,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.tranon.2021.101063","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T05:54:09Z","timestamp":1615528449000},"page":"101063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["The current landscape of the FDA approved companion diagnostics"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-0006","authenticated-orcid":false,"given":"Jan Tr\u00f8st","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2021.101063_bib0001","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","article-title":"HER2 and Breast Cancer - A Phenomenal Success Story","volume":"381","author":"Hayes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101063_bib0002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cell.2019.08.027","article-title":"Herceptin: a first assault on oncogenes that launched a revolution","volume":"179","author":"Sawyers","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2021.101063_bib0003","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.trecan.2016.10.013","article-title":"Companion and complementary diagnostics: clinical and regulatory perspectives","volume":"2","author":"J\u00f8rgensen","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.tranon.2021.101063_bib0004","unstructured":"FDA. List of cleared or approved companion diagnostic devices (In Vitro and Imaging Tools). Update: 11\/16\/2020. ( https:\/\/www.fda.gov\/medical-devices\/vitro-diagnostics\/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools ). Accessed January 12, 2021"},{"key":"10.1016\/j.tranon.2021.101063_bib0005","unstructured":"FDA. Guidance for industry and food and drug administration staff. In vitro companion diagnostic devices. 2014 ( https:\/\/www.fda.gov\/media\/81309\/download ). Accessed January 14, 2021"},{"key":"10.1016\/j.tranon.2021.101063_bib0006","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cpt.955","article-title":"Clinical and regulatory aspects of companion diagnostic development in oncology","volume":"103","author":"J\u00f8rgensen","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tranon.2021.101063_bib0007","unstructured":"FDA. Drugs@FDA: FDA-Approved Drugs. (https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=206995). Accessed February 17, 2021."},{"key":"10.1016\/j.tranon.2021.101063_bib0008","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101063_bib0009","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2021.101063_bib0010","unstructured":"FDA. Humanitarian Device Exemption. Update: 09\/05\/2019 (https:\/\/www.fda.gov\/medicaldevices\/deviceregulationandguidance\/howtomarketyourdevice\/premarketsubmissions\/humanitariandeviceexemption\/default.htm). Accessed January 15, 2021."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:45:40Z","timestamp":1761835540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1936523321000553"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101063","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current landscape of the FDA approved companion diagnostics","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101063"}}